Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Palix Foundation has pledged £265,250 to support a cross-disciplinary project aimed at sharing scientific knowledge about early brain development and its effect on mental health and addiction. The project will be delivered by the Department of Psychiatry and the Department of Experimental Psychology, and will unite Oxford and the foundation's shared vision of improving outcomes for children, their families and future generations.

© THE BRAIN STORY © PALIX FOUNDATION / ALBERTA FAMILY WELLNESS INITIATIVE

Lifelong health is determined by more than just our genes: experiences early in life and at other sensitive periods of development can affect our brains in ways that may impact our health as we grow older. This knowledge has important implications for both policy and practice, but despite its significance, the science behind early brain development is not widely disseminated. Front-line staff may be unfamiliar with recent advances in the field, while parents have little exposure to the science underlying the growth of their children's brains.

The Palix Foundation seeks to bridge this gap. In 2010 the foundation began disseminating the Brain Story, a narrative framework that makes scientific knowledge about early brain development accessible to policy-makers, practitioners and the public. Developed by the FrameWorks Institute and the National Scientific Council of the Developing Child, the Brain Story is shared via tools, resources and a certification course, with the aim of building resilience in families and communities around the world.

With the foundation's support, a team of researchers at Oxford will now work to embed the Brain Story locally and beyond. Under the leadership of Alan Stein, Professor of Child and Adolescent Psychiatry at the University, the team will develop a programme to explore and evaluate different ways of implementing the Brain Story, thus maximising its reach and impact.

Read more (University of Oxford Development Office)

Similar stories

Human challenge trial launches to study immune response to COVID-19

Clinical Trials Coronavirus COVID-19 General

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.